Family-owned Italian biopharmaceutical group Dompe Farmaceutici is considering a listing of its shares as it looks to focus more on its biotech business and treating specific diseases.
“In 3-4 years we could consider a flotation perhaps in the U.S.,” Chief Executive Sergio Dompe said.
Dompe, son of company founder Franco Dompe, said other options also existed, including a reverse merger – or buying a listed business – in the United States, one of the company’s key markets.
The CEO said private equity firms, as well as some European and U.S. industrial players, had made contact with a view to buying the company.
“I told them not to bother since I will never sell,” he said.
Italy has a thriving pharmaceutical sector. But it is fragmented and analysts believe it could benefit from consolidation.
In June, family-controlled Recordati was snapped up by a consortium of investment funds controlled by CVC Capital Partners in a deal worth about 3 billion euros ($3.4 billion).
Dompe Farmaceutici, headquartered in Milan, employs around 800 people and had sales last year of 250 million euros.
Six patients dead after New Jersey virus outbreak
Earlier this year the U.S. Food and Drug Administration approved its new product based on cenegermin – the first drug for the treatment of rare eye disease neurotrophic keratitis.
Dompe, who hopes to be able to market the new treatment in China, said the new cenegermin-based drug was a game changer that could help boost margins over time and support investments in research and development.
“I’m looking to make this company a pharmaceutical biotech business with a focus on particular diseases,” Dompe said. ($1 = 0.8786 euros)
By Stephen Jewkes
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.